These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

617 related articles for article (PubMed ID: 24830390)

  • 1. (G2019S) LRRK2 causes early-phase dysfunction of SNpc dopaminergic neurons and impairment of corticostriatal long-term depression in the PD transgenic mouse.
    Chou JS; Chen CY; Chen YL; Weng YH; Yeh TH; Lu CS; Chang YM; Wang HL
    Neurobiol Dis; 2014 Aug; 68():190-9. PubMed ID: 24830390
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective expression of Parkinson's disease-related Leucine-rich repeat kinase 2 G2019S missense mutation in midbrain dopaminergic neurons impairs dopamine release and dopaminergic gene expression.
    Liu G; Sgobio C; Gu X; Sun L; Lin X; Yu J; Parisiadou L; Xie C; Sastry N; Ding J; Lohr KM; Miller GW; Mateo Y; Lovinger DM; Cai H
    Hum Mol Genet; 2015 Sep; 24(18):5299-312. PubMed ID: 26123485
    [TBL] [Abstract][Full Text] [Related]  

  • 3. (G2019S) LRRK2 activates MKK4-JNK pathway and causes degeneration of SN dopaminergic neurons in a transgenic mouse model of PD.
    Chen CY; Weng YH; Chien KY; Lin KJ; Yeh TH; Cheng YP; Lu CS; Wang HL
    Cell Death Differ; 2012 Oct; 19(10):1623-33. PubMed ID: 22539006
    [TBL] [Abstract][Full Text] [Related]  

  • 4. G2019S LRRK2 and aging confer susceptibility to proteasome inhibitor-induced neurotoxicity in nigrostriatal dopaminergic system.
    Xiao Q; Yang S; Le W
    J Neural Transm (Vienna); 2015 Dec; 122(12):1645-57. PubMed ID: 26253900
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Parkinson's Disease-Linked LRRK2-G2019S Mutation Alters Synaptic Plasticity and Promotes Resilience to Chronic Social Stress in Young Adulthood.
    Matikainen-Ankney BA; Kezunovic N; Menard C; Flanigan ME; Zhong Y; Russo SJ; Benson DL; Huntley GW
    J Neurosci; 2018 Nov; 38(45):9700-9711. PubMed ID: 30249796
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Altered Development of Synapse Structure and Function in Striatum Caused by Parkinson's Disease-Linked LRRK2-G2019S Mutation.
    Matikainen-Ankney BA; Kezunovic N; Mesias RE; Tian Y; Williams FM; Huntley GW; Benson DL
    J Neurosci; 2016 Jul; 36(27):7128-41. PubMed ID: 27383589
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LRRK2 BAC transgenic rats develop progressive, L-DOPA-responsive motor impairment, and deficits in dopamine circuit function.
    Sloan M; Alegre-Abarrategui J; Potgieter D; Kaufmann AK; Exley R; Deltheil T; Threlfell S; Connor-Robson N; Brimblecombe K; Wallings R; Cioroch M; Bannerman DM; Bolam JP; Magill PJ; Cragg SJ; Dodson PD; Wade-Martins R
    Hum Mol Genet; 2016 Mar; 25(5):951-63. PubMed ID: 26744332
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhanced striatal dopamine transmission and motor performance with LRRK2 overexpression in mice is eliminated by familial Parkinson's disease mutation G2019S.
    Li X; Patel JC; Wang J; Avshalumov MV; Nicholson C; Buxbaum JD; Elder GA; Rice ME; Yue Z
    J Neurosci; 2010 Feb; 30(5):1788-97. PubMed ID: 20130188
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synaptic dysfunction in Parkinson's disease.
    Picconi B; Piccoli G; Calabresi P
    Adv Exp Med Biol; 2012; 970():553-72. PubMed ID: 22351072
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Age-dependent dopamine transporter dysfunction and Serine129 phospho-α-synuclein overload in G2019S LRRK2 mice.
    Longo F; Mercatelli D; Novello S; Arcuri L; Brugnoli A; Vincenzi F; Russo I; Berti G; Mabrouk OS; Kennedy RT; Shimshek DR; Varani K; Bubacco L; Greggio E; Morari M
    Acta Neuropathol Commun; 2017 Mar; 5(1):22. PubMed ID: 28292328
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuronal Firing and Glutamatergic Synapses in the Substantia Nigra Pars Reticulata of LRRK2-G2019S Mice.
    Sitzia G; Skiteva O; Chergui K
    Biomolecules; 2022 Nov; 12(11):. PubMed ID: 36358985
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Behavioral deficits and striatal DA signaling in LRRK2 p.G2019S transgenic rats: a multimodal investigation including PET neuroimaging.
    Walker MD; Volta M; Cataldi S; Dinelle K; Beccano-Kelly D; Munsie L; Kornelsen R; Mah C; Chou P; Co K; Khinda J; Mroczek M; Bergeron S; Yu K; Cao LP; Funk N; Ott T; Galter D; Riess O; Biskup S; Milnerwood AJ; Stoessl AJ; Farrer MJ; Sossi V
    J Parkinsons Dis; 2014; 4(3):483-98. PubMed ID: 25000966
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adenoviral-mediated expression of G2019S LRRK2 induces striatal pathology in a kinase-dependent manner in a rat model of Parkinson's disease.
    Tsika E; Nguyen AP; Dusonchet J; Colin P; Schneider BL; Moore DJ
    Neurobiol Dis; 2015 May; 77():49-61. PubMed ID: 25731749
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Temporal expression of mutant LRRK2 in adult rats impairs dopamine reuptake.
    Zhou H; Huang C; Tong J; Hong WC; Liu YJ; Xia XG
    Int J Biol Sci; 2011; 7(6):753-61. PubMed ID: 21698001
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chronic and acute LRRK2 silencing has no long-term behavioral effects, whereas wild-type and mutant LRRK2 overexpression induce motor and cognitive deficits and altered regulation of dopamine release.
    Volta M; Cataldi S; Beccano-Kelly D; Munsie L; Tatarnikov I; Chou P; Bergeron S; Mitchell E; Lim R; Khinda J; Lloret A; Bennett CF; Paradiso C; Morari M; Farrer MJ; Milnerwood AJ
    Parkinsonism Relat Disord; 2015 Oct; 21(10):1156-63. PubMed ID: 26282470
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Functional alterations of the dopaminergic and glutamatergic systems in spontaneous α-synuclein overexpressing rats.
    Guatteo E; Rizzo FR; Federici M; Cordella A; Ledonne A; Latini L; Nobili A; Viscomi MT; Biamonte F; Landrock KK; Martini A; Aversa D; Schepisi C; D'Amelio M; Berretta N; Mercuri NB
    Exp Neurol; 2017 Jan; 287(Pt 1):21-33. PubMed ID: 27771352
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of LRRK2 Inhibitors on Nigrostriatal Dopaminergic Neurotransmission.
    Qin Q; Zhi LT; Li XT; Yue ZY; Li GZ; Zhang H
    CNS Neurosci Ther; 2017 Feb; 23(2):162-173. PubMed ID: 27943591
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dopamine D2 receptor activation potently inhibits striatal glutamatergic transmission in a G2019S LRRK2 genetic model of Parkinson's disease.
    Tozzi A; Durante V; Bastioli G; Mazzocchetti P; Novello S; Mechelli A; Morari M; Costa C; Mancini A; Di Filippo M; Calabresi P
    Neurobiol Dis; 2018 Oct; 118():1-8. PubMed ID: 29908325
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Motor Impairments and Dopaminergic Defects Caused by Loss of Leucine-Rich Repeat Kinase Function in Mice.
    Huang G; Bloodgood DW; Kang J; Shahapal A; Chen P; Kaganovsky K; Kim JI; Ding JB; Shen J
    J Neurosci; 2022 Jun; 42(23):4755-4765. PubMed ID: 35534227
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Altered long-term corticostriatal synaptic plasticity in transgenic mice overexpressing human CU/ZN superoxide dismutase (GLY(93)-->ALA) mutation.
    Geracitano R; Paolucci E; Prisco S; Guatteo E; Zona C; Longone P; Ammassari-Teule M; Bernardi G; Berretta N; Mercuri NB
    Neuroscience; 2003; 118(2):399-408. PubMed ID: 12699776
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.